Recursion Pharmaceuticals Inc Cl A RXRX

$3.19 -0.15 (-4.35%)

Valuation

Market cap
2,235,705,000
Revenue TTM
$74,680,000
Net income TTM
$-644,760,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-863.36%
Debt to equity
0.00

Trading

Volume
16,484,114
Avg volume
25,093,852
Day's range
$3.16 – $3.34
Shares out
622,759,000
Stochastic %K
7%
Beta
1.15
Analysts
Moderate Buy
Price target
$6.99

Price

Company profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-...

Show more

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Industry
Biotechnology
Sector
Healthcare
Phone
385 269 0203
Website
https://www.recursion.com
Address
41 South Rio Grande Street, Salt Lake City, United States

Latest news

Stocktwits

Niconicai Nov 13, 9:02 PM
$RXRX Correct me if I am wrong. REC-4881 is highly likely to be the first domestic U.S. AI drug to enter an FDA registrational clinical pathway. This marks a major milestone for the U.S. AI drug discovery industry.
0 replies
MrShort7 Nov 13, 8:57 PM
$RXRX shorts, please take it into the 2’s, I would like to afford more shares and it helps at a lower cost. Thanks in advance
0 replies
Niconicai Nov 13, 8:02 PM
$RXRX Added more at $3.2. Let’s see 🤷🏼 FDA news could drop anytime.
0 replies
Spartangio Nov 13, 5:56 PM
$RXRX ARK added 3.41M shares during Q3 (+8.24%), reaching 44.75M shares as of Sept. 30—before its participation in October’s offering. Let Cathie cook 👩‍🍳🧬
0 replies
NatesNotes Nov 13, 5:32 PM
After being recommended at just under $0.24 (adj. for splits) back in June of 1998, today's push above $360 has made $AAPL the newsletter's second-ever "1,500-bagger" ($NVDA was the first, having been recommended at just under $0.11, also adj. for splits, in November 2002)! Two other stocks we like today (and will likely also hold in the newsletter "forever"... unless/until they get bought out, of course) are $RXRX and $MNKD, both of which also have the potential to generate significant long-term gains for investors from current prices! Here's to the power of taking a disciplined, "whole portfolio" approach to long-term investing! Cheers!
2 replies
CoffeeRocks Nov 13, 5:15 PM
$IBRX $RXRX $SLS Sure look at $MRNA 20$-240$
1 replies
Floridaorange Nov 13, 5:13 PM
$IBRX $RXRX $SLS Sls results drop any day and it’s barely green today after yesterday’s ah rally it sunk at open, meaning its a sector beating nothing personal.
0 replies
ReversalRuler Nov 13, 3:37 PM
Thanks for the tips bro I made 14k! Follow this guy @SqueezeSpecs he's on fire🔥 $EOSE $RXRX $ITUB 🔥
0 replies